세계의 양극성 장애 치료제 시장 보고서(2025년)

Bipolar disorder therapeutics consist of medications such as mood stabilizers, antidepressants, antipsychotics, and psychological counseling aimed at controlling symptoms associated with bipolar disorders. These therapeutics play a crucial role in the treatment and management of bipolar disorders.

The primary categories of drugs within bipolar disorder therapeutics include mood stabilizers, antipsychotic drugs, antidepressant drugs, and other medications. Mood stabilizers constitute a class of drugs specifically designed for the management and treatment of bipolar disorders. Various mechanisms are employed, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These drugs are commonly available through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The bipolar disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.44 billion in 2024 to $7.82 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to rise in medical research and developments, increased healthcare expenditure, rise in prevalence of mental health disorders, rise in patient advocacy.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $9.82 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing prevalence of bipolar disorder, government initiatives, expansion of healthcare infrastructure, growing adoption of a sedentary lifestyle. Major trends in the forecast period include personalized treatment approaches, digital health integration, innovative medications, preventive interventions, neuroimaging and biomarkers.

The forecast of 5.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. mental healthcare by increasing the cost of mood stabilizers and antipsychotic medications sourced from India and Israel, thereby reducing treatment adherence and elevating psychiatric care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising healthcare expenditure is projected to drive the growth of the bipolar disorder therapeutics market in the future. Healthcare infrastructure encompasses all expenses related to medical care, preventive measures, public health initiatives, rehabilitation, community health activities, and health research. Several factors contribute to the increase in healthcare spending, including an aging population, a surge in chronic diseases, and escalating drug costs, all of which significantly heighten the demand for medical services and treatments. As awareness of mental health issues grows, the diagnosis of bipolar disorder is also on the rise, resulting in greater demand for therapeutic interventions. For example, in November 2023, the Canadian Institute for Health Information, a non-profit organization based in Canada, projected that total health spending in Canada would increase by 2.8% in 2023, following a modest growth of just 1.5% in 2022. Thus, the increasing healthcare expenditure is fueling the growth of the bipolar disorder therapeutics market.

The growing demand for psychological counseling is expected to significantly contribute to the expansion of the bipolar disorder therapeutics market. Psychological counseling, a form of therapy aimed at improving mental health and enhancing overall quality of life, plays a crucial role in managing symptoms of bipolar disorder. Psychotherapy helps individuals identify triggers for bipolar episodes and equips them with coping mechanisms for stressors. According to The Centers for Disease Control and Prevention (CDC), from 2019 to 2021, there was an increase in the percentages of both men and women aged 18-44 in the U.S. who received any mental health treatment in the past 12 months. The surge in demand for psychological counseling underscores a critical aspect of bipolar disorder therapeutics, driving the market forward.

Strategic partnerships have become a prominent trend in the bipolar disorder therapeutics market. Major companies in this sector are increasingly focusing on collaborations to strengthen their market position. For example, in April 2022, BioXcel Therapeutics, Inc., a biopharmaceutical company based in the US, received FDA approval for IGALMITM (dexmedetomidine), a sublingual film designed for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. This film dissolves in the mouth and is specifically formulated to address mild, moderate, or severe agitation in these patient groups. The drug is engineered for rapid onset of action, allowing for effective management of agitation episodes.

Major companies in the Bipolar Disorder Therapeutics and related market are focusing on developing new treatments for depressive episodes linked to bipolar I or II disorder in order to reach larger customer bases, boost sales, and increase revenue. Among the various types of bipolar disorders, bipolar depression represents the most common and severe clinical manifestation. Compared to manic or hypomanic episodes, these depressive episodes are associated with a worse prognosis, longer duration, and more frequent recurrences. For example, in March 2024, the EDIT-B consortium, a collaborative organization based in France that specializes in innovative diagnostic tools and biomarkers, launched myEDIT-B, a novel blood diagnostic tool designed to provide objective biological data to assist psychiatrists and healthcare professionals in making accurate diagnoses. This tool analyzes RNA editing-based biomarkers and has demonstrated sensitivity and specificity rates exceeding 80%. By enabling faster and more precise diagnoses-potentially reducing wait times to within four weeks-myEDIT-B aims to address the significant issue of misdiagnosis in mental health, with approximately 40% of individuals diagnosed with depression possibly having bipolar disorder instead.

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, made a strategic move by acquiring the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd., the terms of which were undisclosed. This acquisition, facilitated by Brain Therapeutics, aims to broaden Neuraxpharm Group's therapeutic product portfolio in Greece and Europe. The agreement positions Neuraxpharm Group to leverage its expertise in the central nervous system (CNS) field, ensuring that Lazap reaches a wider audience. Lyofin Ltd., the Greek pharmaceutical company, is a key player in this collaboration, contributing to the expansion of Neuraxpharm Group's offerings in the CNS therapeutic domain. This strategic move reflects the industry's dedication to meeting healthcare demands by enhancing its product portfolio and geographical reach.

Major companies operating in the bipolar disorder therapeutics market include AbbVie Inc., Pfizer Inc., Astellas Pharma Inc, AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd, H. Lundbeck A/S, Janssen Pharmaceuticals, Sanofi S.A., Lundbeck A/S, Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Celon Pharma SA, NeuroRx Inc., IntraCellular Therapies Inc., Sumitomo Pharma Co. Ltd., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

North America was the largest region in the bipolar disorder therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bipolar Disorder Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bipolar disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bipolar disorder therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bipolar disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Mood Stabilizers; Antipsychotic Drugs; Antidepressant Drugs; Other Drugs
• 2) By Mechanism: Selective Serotonin Reuptake Inhibitors; Serotonin-norepinephrine Reuptake Inhibitors; Tricyclic Antidepressants; Monoamine Oxidase Inhibitors; Benzodiazepines; Beta-Blockers; Other Mechanisms
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Mood Stabilizers: Lithium; Anticonvulsants; Calcium Channel Blockers
• 2) By Antipsychotic Drugs: Atypical Antipsychotics; Typical Antipsychotics
• 3) By Antidepressant Drugs: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs)
• 4) By Other Drugs: Benzodiazepines; Adjunctive Therapies; Herbal Supplements
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Astellas Pharma Inc; AstraZeneca PLC; Bristol-Myers Squibb; GlaxoSmithKline PLC; Januaryssen Pharmaceuticals; Novartis AG; Otsuka Pharmaceutical Co. Ltd.; Validus Pharmaceuticals; Eli Lilly and Company; Gedeon Richter PLC.; Sumitomo Pharma Co. Ltd; H. Lundbeck A/S; Janssen Pharmaceuticals; Sanofi S.A.; Lundbeck A/S; Allergan plc; Takeda Pharmaceutical Company Limited; Sunovion Pharmaceuticals Inc.; Alkermes plc; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Johnson & Johnson; Celon Pharma SA; NeuroRx Inc.; IntraCellular Therapies Inc.; Sumitomo Pharma Co. Ltd.; Vanda Pharmaceuticals Inc.; Sage Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bipolar Disorder Therapeutics Market Characteristics

3. Bipolar Disorder Therapeutics Market Trends And Strategies

4. Bipolar Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Bipolar Disorder Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bipolar Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bipolar Disorder Therapeutics Market Growth Rate Analysis
• 5.4. Global Bipolar Disorder Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bipolar Disorder Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bipolar Disorder Therapeutics Total Addressable Market (TAM)

6. Bipolar Disorder Therapeutics Market Segmentation

• 6.1. Global Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mood Stabilizers
• Antipsychotic Drugs
• Antidepressant Drugs
• Other Drugs
• 6.2. Global Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors
• Serotonin-norepinephrine Reuptake Inhibitors
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Benzodiazepines
• Beta-Blockers
• Other Mechanisms
• 6.3. Global Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Bipolar Disorder Therapeutics Market, Sub-Segmentation Of Mood Stabilizers, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lithium
• Anticonvulsants
• Calcium Channel Blockers
• 6.5. Global Bipolar Disorder Therapeutics Market, Sub-Segmentation Of Antipsychotic Drugs, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.6. Global Bipolar Disorder Therapeutics Market, Sub-Segmentation Of Antidepressant Drugs, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• 6.7. Global Bipolar Disorder Therapeutics Market, Sub-Segmentation Of Other Drugs, By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benzodiazepines
• Adjunctive Therapies
• Herbal Supplements

7. Bipolar Disorder Therapeutics Market Regional And Country Analysis

• 7.1. Global Bipolar Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bipolar Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bipolar Disorder Therapeutics Market

• 8.1. Asia-Pacific Bipolar Disorder Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bipolar Disorder Therapeutics Market

• 9.1. China Bipolar Disorder Therapeutics Market Overview
• 9.2. China Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bipolar Disorder Therapeutics Market

• 10.1. India Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bipolar Disorder Therapeutics Market

• 11.1. Japan Bipolar Disorder Therapeutics Market Overview
• 11.2. Japan Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bipolar Disorder Therapeutics Market

• 12.1. Australia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bipolar Disorder Therapeutics Market

• 13.1. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bipolar Disorder Therapeutics Market

• 14.1. South Korea Bipolar Disorder Therapeutics Market Overview
• 14.2. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bipolar Disorder Therapeutics Market

• 15.1. Western Europe Bipolar Disorder Therapeutics Market Overview
• 15.2. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bipolar Disorder Therapeutics Market

• 16.1. UK Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bipolar Disorder Therapeutics Market

• 17.1. Germany Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bipolar Disorder Therapeutics Market

• 18.1. France Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bipolar Disorder Therapeutics Market

• 19.1. Italy Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bipolar Disorder Therapeutics Market

• 20.1. Spain Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bipolar Disorder Therapeutics Market

• 21.1. Eastern Europe Bipolar Disorder Therapeutics Market Overview
• 21.2. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bipolar Disorder Therapeutics Market

• 22.1. Russia Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bipolar Disorder Therapeutics Market

• 23.1. North America Bipolar Disorder Therapeutics Market Overview
• 23.2. North America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bipolar Disorder Therapeutics Market

• 24.1. USA Bipolar Disorder Therapeutics Market Overview
• 24.2. USA Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bipolar Disorder Therapeutics Market

• 25.1. Canada Bipolar Disorder Therapeutics Market Overview
• 25.2. Canada Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bipolar Disorder Therapeutics Market

• 26.1. South America Bipolar Disorder Therapeutics Market Overview
• 26.2. South America Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bipolar Disorder Therapeutics Market

• 27.1. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bipolar Disorder Therapeutics Market

• 28.1. Middle East Bipolar Disorder Therapeutics Market Overview
• 28.2. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bipolar Disorder Therapeutics Market

• 29.1. Africa Bipolar Disorder Therapeutics Market Overview
• 29.2. Africa Bipolar Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bipolar Disorder Therapeutics Market, Segmentation By Mechanism, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bipolar Disorder Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bipolar Disorder Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Bipolar Disorder Therapeutics Market Competitive Landscape
• 30.2. Bipolar Disorder Therapeutics Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

31. Bipolar Disorder Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Januaryssen Pharmaceuticals
• 31.3. Novartis AG
• 31.4. Otsuka Pharmaceutical Co. Ltd.
• 31.5. Validus Pharmaceuticals
• 31.6. Eli Lilly and Company
• 31.7. Gedeon Richter PLC.
• 31.8. Sumitomo Pharma Co. Ltd
• 31.9. H. Lundbeck A/S
• 31.10. Janssen Pharmaceuticals
• 31.11. Sanofi S.A.
• 31.12. Lundbeck A/S
• 31.13. Allergan plc
• 31.14. Takeda Pharmaceutical Company Limited
• 31.15. Sunovion Pharmaceuticals Inc.

32. Global Bipolar Disorder Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bipolar Disorder Therapeutics Market

34. Recent Developments In The Bipolar Disorder Therapeutics Market

35. Bipolar Disorder Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Bipolar Disorder Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bipolar Disorder Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bipolar Disorder Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer